- Home
- GENK vs XCUR Comparison
GENK vs XCUR Comparison
Compare GENK & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | XCUR |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 13.7M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GENK | XCUR |
|---|---|---|
| Price | $1.95 | $2.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | 18.3K | ★ 32.9K |
| Earning Date | 05-13-2026 | 03-25-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | 62.50 | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.43 | $1.71 |
| 52 Week High | $4.98 | $9.50 |
Technical Indicators
Market Signals| Indicator | GENK | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 36.60 |
| Support Level | $1.72 | $1.71 |
| Resistance Level | $2.31 | $3.40 |
| Average True Range (ATR) | 0.14 | 0.39 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 8.97 | 38.26 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
About XCUR Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.